Advertisement

Annals of Hematology

, Volume 97, Issue 8, pp 1487–1488 | Cite as

Major response of PNH to an AML chemotherapy protocol

  • Wolfgang Füreder
  • Wolfgang R. Sperr
  • Karoline Gleixner
  • Renate Thalhammer
  • Ilse Schwarzinger
  • Gregor Hoermann
  • Christoph Kornauth
  • Birgit Grünberger
  • Peter Valent
Letter to the Editor
  • 100 Downloads

Dear Editor,

Although treatment with eculizumab has revolutionized therapy of paroxysmal nocturnal hemoglobinuria (PNH), no curative therapy is available except allogeneic hematopoietic stem cell transplantation [ 1]. We report on a 64-year-old male patient suffering from PNH with concomitant acute myeloid leukemia (AML). PNH was diagnosed in August 2014. Because of anemia, treatment with eculizumab was started. In 2015, the patient developed a high-risk myelodysplastic syndrome (subtype: refractory anemia with excess of blasts) and received 6 cycles of 5-azacitidine. Despite therapy with 5-azacitidine, the patient progressed to an overt AML in March 2016. Blast cells amounted to 40% in the bone marrow (BM) and 8% in the peripheral blood (PB). No cytogenetic or molecular aberrations were detected. Glycosyl-phosphatidyl-inositol (GPI)-deficient neutrophil clone size prior to chemotherapy was 92%. The patient received remission-induction chemotherapy consisting of ARA-C and daunorubicin...

Notes

Author contributions

WF and PV designed the study and wrote the manuscript. WRS, KG, and BG collected and analyzed data. RT and IS performed flow cytometry experiments. CK analyzed the bone marrow biopsies. GH performed molecular studies. All authors reviewed and approved the manuscript.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Conflict of interest

WF received honoraria from Alexion. PV received honoraria from Alexion and Celgene and a research grant from Celgene.

References

  1. 1.
    Hill A, Richards SJ, Hillmen P (2007) Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 137:181–192CrossRefPubMedGoogle Scholar
  2. 2.
    Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60:454–462PubMedGoogle Scholar
  3. 3.
    Hirsch VJ, Neubach PA, Parker DM, Reese MH, Stone MJ (1981) Paroxysmal nocturnal hemoglobinuria. Termination in acute myelomonocytic leukemia and reappearance after leukemic remission. Arch Intern Med 141:525–527CrossRefPubMedGoogle Scholar
  4. 4.
    Krause JR (1983) Paroxysmal nocturnal hemoglobinuria and acute non-lymphocytic leukemia. A report of three cases exhibiting different cytologic types. Cancer 51:2078–2082CrossRefPubMedGoogle Scholar
  5. 5.
    Kawano F, Chosa M, Matsuoka M, Oyamada N, Takatsuki K (1987) Paroxysmal nocturnal hemoglobinuria: termination in acute monocytic leukemia and reappearance after chemotherapy with N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) and vincristine. Jpn J Clin Oncol 17:123–128PubMedGoogle Scholar
  6. 6.
    Cornélis F, Montfort L, Osselaer JC, Sonet A, Doyen C, Chatelain C, Chatelain B, Bosly A (1996) Acute leukaemia in paroxysmal nocturnal haemoglobinuria. Case report and review of the literature. Hematol Cell Ther 38:285–288CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Wolfgang Füreder
    • 1
  • Wolfgang R. Sperr
    • 1
  • Karoline Gleixner
    • 1
  • Renate Thalhammer
    • 2
  • Ilse Schwarzinger
    • 2
  • Gregor Hoermann
    • 2
  • Christoph Kornauth
    • 3
  • Birgit Grünberger
    • 4
  • Peter Valent
    • 1
  1. 1.Department of Internal Medicine I, Division of Hematology and HemostaseologyMedical University of ViennaViennaAustria
  2. 2.Department of Laboratory MedicineMedical University of ViennaViennaAustria
  3. 3.Department of Clinical PathologyMedical University of ViennaViennaAustria
  4. 4.Department of OncologyLandesklinikum Wr NeustadtNeustadtAustria

Personalised recommendations